H eart failure (HF) is a common cause of death and disability. 1 Altered signal transduction via β-adrenoceptors (βARs) and G proteins is a hallmark of chronic HF and contributes to impaired cardiac contractility. 2, 3 The exact molecular pathophysiological mechanisms contributing to contractile dysfunction in patients with HF are incompletely understood, and a better understanding of these processes is expected to foster the development of improved treatment options for patients with HF. 3 The plasma-membrane content of nucleoside diphosphate kinases (NDPKs) is increased in patients with endstage HF, 4 pointing to a potential role for NDPKs in HF. NDPKs represent a family of multifunctional proteins encoded by 10 human nm23 genes, of which the class I subfamily (consisting of NDPK-A, -B, -C, and -D) exerts enzymatic activity. 5 NDPKs form heterohexamers and catalyze the transfer of γ-phosphate between nucleotide triphosphates and nucleotide diphosphates. 6, 7 NDPK-A and NDPK-B play a role in numerous cellular processes, often as part of larger signaling complexes. For example, NDPK-B, but not NDPK-A, forms complexes with Gβγ dimers and acts as a protein histidine kinase that can activate cardiac G proteins in a receptor-independent manner. [8] [9] [10] Nevertheless, our previous studies indicated that the complex between NDPK-B and G proteins cannot be reconstituted in vitro, suggesting that NDPK-B alone is insufficient to regulate G-protein signaling and that an as-yet unidentified key cofactor is required for the complex formation of NDPK-B and G proteins at the plasma membrane. 10 NDPK-C exerts enzymatic activity and is able to form heterohexamers with NDPK-A and NDPK-B.
11 NDPK-C shares 72% homology with NDPK-A and NDPK-B but has an additional hydrophobic N-terminal domain ( Figure I in the online-only Data Supplement), which could serve as a membrane anchor. 12, 13 NDPK-C is generally less abundantly expressed than the major isoforms NDPK-A and NDPK-B 11 but is highly enriched at the cardiac plasma membrane of patients with HF.
14 Thus, NDPK-C might be the limiting factor targeting NDPK hexamers to membranous G proteins and could be the most relevant NDPK isoform for cAMP regulation in the heart and for the progression of HF. However, the function of NDPK-C in the heart is unknown.
To investigate the role of NDPK-C in HF, we performed biochemical studies of NDPK-C and G-protein signaling in human and rat tissue samples, assessed the functional impact of NDPK-C on cAMP levels and cardiac contractility in isolated rat cardiomyocytes, and determined the in vivo effects of NDPKs on contractility in zebrafish and mice. We identify NDPK-C as the critical isoform for the regulation of G-protein function and cAMP levels in the heart, with important consequences for cardiac contractility. Our results show that NDPK-C can interact promiscuously with both Gα s and Gα i proteins. The switch to Gα i2 -dominant regulation of G proteins by NDPK-C in human HF may contribute to the lower cAMP levels and impaired contractility characteristic of this clinical condition.
METHODS
A detailed overview of all methods is provided in the online-only Data Supplement. Key aspects are summarized below.
Tissue Procurement
Nonfailing human myocardium from the free wall of the left ventricle was obtained from organ donors with no apparent heart disease and normal left ventricular function (determined by echocardiography) for whom no suitable heart transplant recipients had been identified. Left ventricular myocardial samples of failing human hearts were obtained from patients with HF (New York Heart Association class III-IV) who underwent cardiac transplantation. The experimental protocol was approved by the ethics review board of the University of Szeged Medical Center. Informed written consent was obtained for the use of nondiseased human hearts. All procedures conformed to the Helsinki Declaration of the World Medical Association.
Clinical Perspective
What Is New?
• We show for the first time that the nucleoside diphosphate kinase (NDPK)-C is required and indispensable for the interaction of NDPKs with both stimulatory G s and inhibitory G i proteins.
• NDPK-C-mediated targeting of NDPKs to the plasma membrane is increased in response to β-adrenoceptor stimulation and enhances intracellular cAMP levels, cardiomyocyte contractility, and in vivo cardiac function.
• We provide novel mechanistic insights into remodeling of β-adrenoceptor signaling in heart failure (HF), showing that the HF-related increase in NDPK-C expression may cause constitutive G i -mediated inhibition of adenylyl cyclases, providing a plausible explanation for the lower cAMP levels in HF.
What Are the Clinical Implications?
• The increased NDPK-C membrane content in human HF could potentially counteract a fading β-adrenoceptor response in the early stages of HF by increasing the amount of Gα s proteins in the plasma membrane. However, by switching to Gα i2 activation, NDPK-C may play a role in HF progression by reducing cAMP levels, typical for end-stage human HF.
• A better understanding of the molecular processes underlying altered G-protein signaling in HF may help to develop new HF therapies. We identify NDPK-C as a novel therapeutic target involved in the regulation of aberrant G-protein signaling and cardiac contractility in HF.
Rat and Mouse Models of Isoprenaline Stimulation and Isolation of Rat Cardiomyocytes
Male Wistar rats received 4 days of either isoprenaline or vehicle administered via osmotic minipumps, as previously described. 15 Male C57Bl/6 wild-type and NDPK-B knockout mice received the same treatment but for 7 days. All animals were anesthetized with 2% isoflurane inhalation and received carprofen (5 µg/kg SC) as analgesic. All procedures concerning the care and use of animals were in accordance with institutional guidelines (Az. G-12\10 Regierungspräsidium Karlsruhe, Germany, and Az. G10\65 LAVES Niedersachsen, Germany).
Generation of Recombinant Adenoviruses
Recombinant adenoviruses were generated as previously described. 8, [16] [17] [18] mRNA Analysis, Transfection and Transduction, Membrane Fractionation, Western Blots, Immunoprecipitation, Far Western Blotting, and ATP/GTP Hydrolysis Assays Details are provided in the online-only Data Supplement. The primers that were used are listed in Table I in the online-only Data Supplement.
Visualization of the Subcellular Localization of NDPK-C
Neonatal rat cardiomyocytes (NRCMs) and adult rat cardiomyocytes (ARCMs) were cultured with serum-free medium on coverslips and infected with Ad-Flag-NDPK-C. Twenty-four hours later, cells were stimulated with solvent or isoprenaline for up to 6 hours. The subcellular localization of NDPK-C was visualized by confocal fluorescence microscopy.
Measurement of Intracellular cAMP
cAMP levels in NRCM or zebrafish lysates were assayed with a cAMP immunoassay. 8, 9, 19 For cAMP assays in living cells, ARCMs were isolated and transduced with Epac2-camps adenovirus, as previously described, 18 together with a control (LacZ) or NDPK-C-encoding adenovirus. Cells were stimulated with isoprenaline, forskolin, and 3-isobutyl-1-methylxanthine.
Fractional Shortening in ARCMs
ARCMs were infected with an adenovirus encoding enhanced green fluorescent protein (Ad-EGFP) or Ad-Flag-NDPK-C. Sarcomere shortening was assessed during field stimulation with a videobased sarcomere-length detection system at 1.25 mmol/L Ca 2+ in the bath solution.
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Zebrafish Maintenance, Morpholino Injection, Measurement of Fractional Shortening, and Histology
Zebrafish danio rerio were maintained under standard conditions. 21 Embryos at a 1-cell stage were injected with the indicated amounts of the NDPK-B or NDPK-C targeting morpholino or a standard control oligonucleotide at the same concentration. Injections and analyses of fractional shortening, ventricular diameters, immunohistochemistry, and electron microscopy were performed as previously described.
19,21

Statistics
Results are presented as mean±SEM. Normality was assessed with the D'Agostino and Pearson omnibus test. The MannWhitney test (for nonnormally distributed data or data with too few points to assess normality), an unpaired 2-tailed Student t test, or 1-or 2-way ANOVA followed by a post hoc Bonferroni or the Tukey test was used to compare means between groups. Values of P<0.05 were considered statistically significant.
RESULTS
Interactions Among NDPK-C, NDPK-B, and G Proteins NDPK-C forms hetero-oligomers with NDPK-A and NDPK-B.
11 Moreover, NDPK-B/Gβγ complexes regulate G-protein activity and membrane content in cardiomyocytes. 8, 19, 22 Therefore, we assessed whether NDPK-C is involved in the complex formation of NDPKs with G proteins using far Western blotting. 10 When the purified heterotrimeric G protein transducin (G t αβγ) 10 was spotted on cellulose membranes and incubated with lysates of control NRCMs or NRCMs with adenovirus-mediated overexpression of NDPK-B, no direct interaction occurred ( Figure 1A ). In contrast, purified G t αβγ showed a strong direct interaction with exogenous Flag-NDPK-C, detected with an anti-Flag antibody, in Flag-NDPK-C overexpressing NRCMs. The putative interaction between NDPK-B and endogenous NDPK-C was confirmed with recombinant NDPK-B spotted on cellulose membranes and incubated with NRCM lysates. Adenovirus-mediated overexpression of NDPK-C further increased the interaction between NDPK-B and NDPK-C ( Figure 1A) . Furthermore, raising the relative NDPK-C content in NRCM lysates with a constant overexpression of NDPK-B (multiplicity of infection, 100) by increasing the multiplicity of infection of the Ad-Flag-NDPK-C virus from 0 to 100 produced a concentration-dependent increase in the binding of NDPK-B to G t αβγ ( Figure 1B ). These data suggest that NDPK-C is essential for the previously detected complex formation between NDPK-B and Gβγ.
ATP/GTP hydrolysis assays were used to analyze the effects of NDPK-B and NDPK-C on the activation of G t αβγ, as monitored by the GTPase activity of its Gα subunit, which does not hydrolyze ATP. Thus, only in the presence of NDPKs can the radiolabeled phosphate group from [ 32 P]ATP be transferred to GDP, forming [ 32 P]GTP, the appropriate G t α-GTPase substrate. The G t αβγ preparation exhibited some ATP hydrolysis capacity, as indicated by the inhibitory effect of the NDPK activity-suppressing uridine 5'-diphosphate (UDP; Figure 1C) . 23 This basal activity can be attributed to the NDPKs copurified in bovine G t αβγ. 10 Addition of purified recombinant NDPK-C, but not NDPK-B, significantly increased ATP hydrolysis. Combining both NDPKs produced a significant additional increase. All increments in ATP hydrolysis were sensitive to UDP, confirming the involvement of the enzymatic activity of NDPKs. 23 Similar results were obtained when GTP hydrolysis was measured ( Figure II in the online-only Data Supplement), supporting an NDPK-C-dependent activation of G t αβγ.
To investigate the interaction between individual Gprotein family members and NDPK-B or NDPK-C, purified NDPK-B and NDPK-C were spotted on cellulose membranes and incubated with lysates of mouse embryonic fibroblasts. Binding of G proteins to these NDPKs was subsequently detected with specific antibodies against Gβ 1 , Gβ 2 , Gα q , Gα s , and Gα i2 . Purified NDPK-B showed no direct interaction with any tested G-protein subunit, whereas NDPK-C strongly interacted with all G-protein subunit compositions tested ( Figure 1D ). To test whether NDPK-C alone can regulate G proteins, independently of NDPK-B, mouse embryonic fibroblasts of NDPK-A/NDPK-B double-knockout mice were used. Cardiac myocytes of these animals were not available because they die shortly after birth. 24 Adenovirus-mediated overexpression of Flag-NDPK-C in NDPK-A/NDPK-B double-knockout mouse embryonic fibroblasts significantly increased the membrane content of Gα s and Gβ 1 ( Figure 1E ), showing that NDPK-C alone is sufficient to regulate G proteins. We then determined whether Gα s and Gα i2 compete for binding to NDPK-C. Different amounts of NRCM lysates overexpressing Gβ 1 γ 2 , Gα s , or Gα i2 ( Figure  III in the online-only Data Supplement) were combined to obtain specific ratios of Gα i2 to Gα s , and the interaction between recombinant NDPK-C and Gα s or Gα i2 proteins was determined with Far Western blots. As expected, 8, 9 recombinantly expressed Gα s or Gα i2 in NRCM lysates bound to NDPK-C in the presence of sufficient amounts of recombinantly expressed Gβ 1 γ 2 ( Figure 1F ). However, increasing the levels of Gα i2 with a fixed amount of Gα s produced a ratio-dependent decrease in the amount of Gα s binding to NDPK-C ( Figure 1F , left). Likewise, increasing Gα s levels for a fixed Gα i2 amount produced a ratio-dependent decrease in the amount of Gα i2 binding to NDPK-C ( Figure 1F , right). Together, these data strongly suggest that NDPK-C is essential for both complex formation of NDPKs with G proteins and the resulting G-protein activation. Moreover, Gα s and Gα i2 proteins directly compete for binding to NDPK-C, and even modest changes in the Gα i2 to Gα s ratio apparently modulate the interaction between NDPK-C and G proteins.
NDPK-C Levels Increase in Response to βAR Stimulation
Using human tissue samples from a previous study, 14 we found a significantly increased membrane protein content of NDPK-A, NDPK-B, and NDPK-C isoforms in failing versus nonfailing hearts ( Figure IV in the online-only Data Supplement), pointing to a role of NDPKs in HF pathophysiology. mRNA levels of NDPK-C, but not NDPK-A and NDPK-B, were significantly increased in HF hearts ( Figure  IV in the online-only Data Supplement), suggesting a selective transcriptional upregulation of NDPK-C in human HF. Patients with HF show a hyperactive sympathetic nervous system with elevated plasma catecholamine levels and subsequent chronic activation of βARs. Therefore, we asked whether chronic βAR stimulation contributes to the NDPK-C upregulation in HF. Compared with saline-infused controls, chronic in vivo βAR stimulation with isoprenaline in rats induced a significant 5-and 14-fold increase in NDPK-B and NDPK-C mRNA content, respectively ( Figure 2A ) but enhanced the protein levels of NDPK-C only ( Figure 2B ). Thus, the increased expression of NDPK-C in patients with HF could directly result from the chronic activation of βARs.
As shown in Figure 2C , NDPK-C and Gα s could be detected in Gβ precipitates from rat ventricular tissue lysates, indicating that NDPK-C interacts with the heterotrimeric G protein. Furthermore, the amount of NDPK-C and Gα s coimmunoprecipitating with Gβ apparently increased after long-term isoprenaline treatment, sug- gesting that isoprenaline not only increases NDPK-C expression but also may enhance the interaction between NDPK-C and G proteins. To verify that these alterations occur in cardiomyocytes, NRCMs were incubated with isoprenaline or solvent for 7 days in vitro. Consistent with the data obtained in human ventricular tissue samples, both mRNA content and protein expression of NDPK-C were increased by in vitro βAR stimulation, whereas the expression of NDPK-B remained unchanged ( Figure 2D and 2E). The interaction between NDPK-B and Gβγ was confirmed in NRCMs and was enhanced by overexpression of NDPK-C ( Figure 2F ), suggesting that NDPK-C is critical for the interaction between NDPK-B and Gβγ in cardiomyocytes.
Subcellular Localization of NDPK-C After βAR Stimulation
NDPK-C was detected predominantly in the cytosol of unstimulated NRCMs. In vitro stimulation of NRCMs with isoprenaline for 6 hours significantly increased the protein levels of NDPK-C at the plasma membrane, with a membrane/cytosol fluorescence ratio of 2.26±0.22 (n=27) versus 0.83±0.10 (n=28) under control condi- Figure 3D ), were also increased. Taken together, these data support the formation of NDPK-C, NDPK-B, and Gprotein complexes, resulting in their enrichment at the plasma membrane after isoprenaline stimulation, and point to a potential role of NDPK-C in the regulation of cellular cAMP synthesis.
NDPK-C Modulates cAMP and Cardiomyocyte Contractility
To study the functional consequences of NDPK-C regulation on cellular cAMP levels, NDPK-C protein levels were reduced by siRNA-mediated knockdown (si-NDPK-C; Figure 4A) or increased by adenovirus-mediated overexpression (Ad-Flag-NDPK-C; Figure 4B ). NDPK-C expression was reduced by 34.8±6.4% with si-NDPK-C compared with si-control ( Figure 4C ), but the use of Ad-Flag-NDPK-C and corresponding anti-Flag antibody precluded quantification of NDPK-C overexpression levels. Modification of NDPK-C protein levels produced parallel changes in Gα s , with significantly reduced Gα s levels in lysates of si-NDPK-C NRCMs, and increased Gα s membrane content in Ad-Flag-NDPK-C NRCMs ( Figure 4C ). Knockdown of NDPK-C expression also significantly reduced cAMP levels, whereas NDPK-C overexpression enhanced cAMP content ( Figure 4D ). Isoprenaline induced a dose-dependent increase in cAMP content with a >50-fold increase in cAMP levels compared with control conditions after maximal stimulation ( Figure 4E ). The increase in isoprenaline-induced cAMP content was significantly reduced in si-NDPK-C NRCMs ( Figure 4E ) but further enhanced by overexpression of NDPK-C ( Figure 4F ). These findings establish a causal relationship between NDPK-C content at the plasma membrane and cellular cAMP levels in NRCMs.
We next determined whether NDPK-C also regulates G proteins and cAMP in ARCMs. NDPK-C levels at the plasma membrane were significantly increased after 6 hours of isoprenaline stimulation in ARCMs ( Figure 5A and 5B). To assess the effects of NDPK-C in living ARCMs, we compared cAMP formation and fractional shortening 8, 20 in ARCMs overexpressing NDPK-C with control ARCMs overexpressing EGFP or LacZ. Isoprenaline-induced cAMP levels were quantified in isolated ARCMs via fluorescent resonance energy transfer with an Epac-derived cAMP sensor. 25, 26 Stimulation of control ARCMs with isoprenaline produced 55±3% of the maximal cAMP response achieved by direct stimulation of adenylyl cyclases with forskolin in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine ( Figure 5C ). In NDPK-Coverexpressing ARCMs, the isoprenaline-induced cAMP response was significantly increased to 70±3% of the maximal cAMP response ( Figure 5C ).The isoprenaline concentrations producing half-maximal cell shortening were significantly higher in the control (4.5±0.9 nmol/L) than in NDPK-C-overexpressing ARCMs (0.8±0.1 nmol/L; Figure 5D ), suggesting that the NDPK-C-induced increase in cAMP affects cardiomyocyte contraction by sensitizing single-cell shortening to βAR stimulation.
Knockdown of NDPK-C Modulates Contractility in Zebrafish
To analyze whether NDPK-C modulates contractility in vivo in a vertebrate organism, we performed morpholinomediated knockdown of NDPK-C in zebrafish embryos. The injection of 300 µmol/L morpholino-NDPK-C caused a loss of NDPK-C protein levels, resulting in phenotypic alterations, including reduced cardiac pump function and pericardial edema, compared with zebrafish injected with a control morpholino at 72 hours after fertilization ( Figure 6A and Supplementary Videos I and II in the online-only Data Supplement). NDPK-C morphant hearts had a normal morphology of endocardial and myocardial cell layers and a regular expression of atrial and ventricular myosin heavy chains ( Figure VIA -VID in the onlineonly Data Supplement). In addition, electron microscopy revealed no differences in the ultrastructure of sarcomeres, z line, and thick and thin filaments ( Figure VIE and VIF in the online-only Data Supplement). Therefore, the structural development of the NDPK-C morphant hearts appears to be unhampered. Functionally, depletion of NDPK-C resulted in decreased basal cAMP levels ( Figure 6B ), similar to that reported previously for zebrafish with knockdown of NDPK-B. 19 Ventricular fractional shortening was progressively reduced from 26.0±1.9% at 48 hours after fertilization to 7.4±1.7% at 72 hours after fertilization in NDPK-C morphants, whereas fractional shortening remained stable in morpholino-control zebrafish ( Figure 6C ). To evaluate synergism between NDPK-C and NDPK-B in vivo, a partial knockdown of NDPK-B and/or NDPK-C was performed with the use of low morpholino concentrations, and ventricular fractional shortening was assessed. Morpholino-NDPK-B (125 µmol/L) or morpholino-NDPK-C (150 µmol/L) alone did not significantly impair ventricular function, whereas their combination severely reduced fractional shortening ( Figure 6D ). To analyze whether an increased NDPK-B expression can substitute for the loss of NDPK-C, we overexpressed NDPK-B, an approach that previously rescued the phenotype caused by morpholino-mediated knockdown of NDPK-B. 19 Compared with controls, NDPK-C morphants frequently showed phenotypic abnormali- ties (eg, pericardial edema or impaired cardiac function; Figure VII in the online-only Data Supplement). NDPK-B overexpression in NDPK-C knockdown embryos did not reduce the incidence of these phenotypic abnormalities ( Figure 6E ). Thus, in accordance with the in vitro data, NDPK-C is apparently indispensable for the complex formation between NDPKs and G proteins, which is involved in cAMP formation and the subsequent alterations in ventricular contractility in vivo.
NDPK-B-Deficient Mice Are Prone to Cardiac Dysfunction
To verify the importance of the complex formation of NDPK-C, NDPK-B, and G proteins described above for cardiac function in mammals, we took advantage of NDPK-B knockout mice. 27 These mice are viable, without obvious phenotype, and have a normal life span. The loss of NDPK-B does not alter the expression of NDPK-C in the heart of these mice ( Figure VIII in the online-only Data Supplement). Nevertheless, at the age of 5 months, they start to develop cardiac dysfunction, as revealed by decreased fractional shortening ( Figure 7A ). To test whether the complex formation of NDPK-B with NDPK-C and G proteins is functionally relevant in the response to chronic βAR stimulation in the mammalian heart, we subjected these mice to the long-term isoprenaline stimulation protocol we used in rats (Figure 2A ) and studied cardiac contractility and remodeling. As shown in Figure 7B through 7D, long-term isoprenaline treatment decreased fractional shortening more strongly in NDPK-B knockout mice than in wild-type controls. In addition, NDPK-B knockout mice were more susceptible to isoprenaline-induced cardiac hypertrophy and fibrosis. Taken together, these data indicate that the complex formation of NDPKs with Gα s proteins, which apparently requires the pres- ence of both NDPK-B and NDPK-C, is beneficial during catecholamine-induced cardiac stress and protects the heart from an early onset of remodeling.
NDPK-C Causes a Switch From Gα s -to Gα iPredominant Signaling in Human HF
The data presented so far identify NDPK-C, by mediating complex formation and membrane targeting of NDPK-B and Gα s , as a regulator with stimulatory effects on cAMP levels and contractility. However, the increased expression of NDPK-C in human HF appears at odds with the reduced contractility observed in patients with HF. On the other hand, our far Western blots indicate that NDPK-C, but not NDPK-B, interacts with both Gα s and Gα i , and the ratio of these proteins determines which G protein is preferentially bound (Figure 1D and 1F) . Therefore, we hypothesized that NDPK-C may switch from Gα s -to Gα i -predominant signaling in human HF, thereby contributing to the lower cAMP levels and reduced cardiomyocyte contractility. To address this hypothesis, we analyzed NDPK-B and NDPK-C expression in ventricular tissue samples from a separate patient cohort. In accordance with the data obtained in the previous collective, 14 NDPK-B and NDPK-C protein levels were significantly increased in tissue lysates of patients with HF compared with healthy donor hearts ( Figure 8A ). The Gα i2 -and Gα sprotein expression in membrane fractions of patients with HF appeared to be slightly increased (20%) and decreased (−15%), respectively, without reaching statistical significance ( Figure 8A and Figure IXA in the onlineonly Data Supplement).
Next, we assessed the interactions among NDPK-C, Gα i2 , and Gα s in ventricular tissue lysates of control samples and those from patients with HF using coimmunoprecipitation. The NDPK-C content of the Gα i2 precipitates was increased 2.8±0.8-fold in patients with HF (P=0.11), whereas the NDPK-C content in the Gα s precipitates of HF samples was decreased to 0.54±0.14-fold of nonfailing controls (P=0.07; Figure IXB in the online-only Data Supplement). Conversely, the amount of Gα i2 that coprecipitated with NDPK-C was increased 2.39±0.35-fold (P<0.05), whereas the amount of Gα s that coprecipitated with NDPK-C was decreased to 0.55±0.08 of nonfailing controls (P<0.05) in human HF, pointing to a switch in the interaction of NDPK-C from Gα s to Gα i2 ( Figure 8B ). cAMP levels were significantly reduced by 42% in patients with HF ( Figure 8C ), consistent with previous results. 28 To determine whether the switch in NDPK/G-protein signaling affects cAMP levels, NRCMs overexpressing EGFP, NDPK-C, Gα i2,, or NDPK-C plus Gα i2 ( Figure 8D ) were incubated with increasing concentrations of isoprenaline. Overexpression of NDPK-C increased the basal and isoprenaline-induced cAMP levels in NRCMs. In contrast, overexpression of Gα i2 reduced the basal cAMP content and the isoprenaline-induced increase in cAMP levels compared with EGFP-expressing controls ( Figure 8E and 8F) . It is notable that overexpression of both NDPK-C and Gα i2 further reduced basal cAMP levels and isoprenalineinduced cAMP production compared with Gα i2 overexpression alone ( Figure 8E and 8F ). These data indicate that the HF-related increase in NDPK-C and the stronger interaction between Gα i2 and NDPK-C ( Figure 8A and 8B) amplify the inhibitory effects of Gα i2 proteins on cardiomyocyte cAMP levels and positions NDPK-C as a novel, potentially critical regulator of Gα i -protein signaling and cellular cAMP in human HF.
DISCUSSION
In the present study, we identified NDPK-C as an essential and indispensable component of the interaction between NDPKs and G proteins. NDPK-C anchors these complexes at the plasma membrane, thereby being an important regulator of cAMP levels and cardiomyocyte contractility. We also discovered that a switch from predominantly Gα s stimulation to Gα i signaling by NDPK-C in human HF might cause the lower cAMP levels in patients with HF. Together, our findings identify NDPK-C as a novel critical regulator of βAR/cAMP signaling that may contribute to contractile dysfunction in HF.
G-Protein Signaling in HF
HF induces complex remodeling, with changes in G-protein signaling as a hallmark of this remodeling process. Long-term sympathetic stimulation results in desensitization of βARs, including reduced expression of β 1 ARs and upregulation of inhibitory G-protein-coupled receptor kinases. 29, 30 In addition, the expression and activity of inhibitory Gα i proteins are increased ≈30% in end-stage HF, 31, 32 and a shift from a prevalence of Gα s -mediated adenylyl cyclase stimulation to Gα i -mediated inhibition of adenylyl cyclases through β 2 -ARs in HF has been reported. 33 The increase in Gα i -protein activity may result partly from transcriptional upregulation of Gα i2 and likely contributes to the impaired βAR responsiveness associated with HF. 34 A modest upregulation of Gα i2 was also identified in the rat model with long-term isoprenaline administration in our study, 35 which suggests that these effects are an adaptive response to chronic sympathetic stimulation. However, in a chronic setting, these changes result in reduced ventricular cardiomyocyte cAMP levels that decrease the activation of protein kinase A in HF. Together with the augmentation of global protein phosphatase activity in HF, 36 the restricted cAMP signaling results in reduced phosphorylation of key cardiac Ca Previous work has shown that the plasma membrane content of NDPK-A, NDPK-B, and NDPK-C is increased in patients with end-stage HF 4 and that long-term activation of βARs increases anchoring of NDPKs to the plasma membrane. 39 Here, we discovered that this increase is due at least in part to a transcriptional upregulation and that NDPK-C is required and indispensable for membrane localization of NDPKs. The human nm23-H3 gene encoding NDPK-C contains active AP-2 sites and a putative CREBP-1 binding site in its promoter region, 40 which are involved in cAMP-dependent regulation of gene transcription 41, 42 and could contribute to the enhancement of NDPK-C protein levels after isoprenaline administration or in end-stage human HF with chronic sympathetic stimulation. Further work is needed to directly test these hypotheses.
Our data on the interaction of NDPK-C with NDPK-B and heterotrimeric G proteins also strongly suggest that NDPK-C is an essential prerequisite for the complex formation of NDPK-C/NDPK-B hetero-oligomers with G proteins. In addition, the lipophilic nature of NDPK-C may allow an easier association with the plasma membrane 43, 44 and is therefore likely the limiting factor for the plasma membrane localization of NDPK isoforms.
Novelty and Potential Clinical Implications
We have identified a novel mechanism by which the plasma membrane content of heterotrimeric G proteins is regulated in cardiomyocytes through NDPK-C. In particular, we show for the first time that NDPK-C is required and indispensable for the interaction between NDPKs and both stimulatory Gα s and inhibitory Gα i proteins, find that NDPK-C-mediated targeting of NDPKs to the plasma membrane is increased in response to βAR stimulation and enhances intracellular cAMP levels, demonstrate that cardiomyocyte contractility in vitro and in vivo is strictly modulated by NDPK-C levels, and provide novel mechanistic insights into cAMP signaling in HF, identifying previously unrecognized molecular targets for the development of new and potentially more effective HF therapy options. Our data put previous studies about regulation of cAMP signaling through NDPKs in a novel and conclusive perspective: NDPK-B can exert its effects on cAMP signaling and contractility only in the presence of NDPK-C, which is responsible for both the membrane targeting and interaction of NDPKs with G proteins. Furthermore, our findings provide a potential mechanistic explanation for why even a small increase in Gα i2 -protein levels and increased membrane-associated NDPKs in HF may inhibit cAMP synthesis 14 and could cause a profound negative inotropic effect. It is interesting to note that modest changes in the Gα s /Gα i ratio ( Figure 1F ), which are in the same range as those reported in HF, 31, 32 may determine which of the G-protein subtypes is bound to NDPK-C. Thus, in the absence of Gα i upregulation, the increased membrane content of NDPK-C in human HF is a mechanism that could potentially counteract a fading βAR response in the early stages of HF by increasing the amount of Gα s proteins at the plasma membrane. However, by switching to Gα i2 activation, NDPK-C could play a role in the progression of the disease and the reduced cAMP levels observed in end-stage human HF. Together, these data provide new insights into the complex alterations in G-protein signaling that are a hallmark of the vicious cycle of chronic sympathetic stimulation in HF and, for the first time, establish increased NDPK-C function as a novel possible molecular facilitator of detrimental Gα iprotein signaling in patients with HF.
Treatment with β-blockers has been the standard therapy for patients with HF. Despite their positive effects on morbidity and mortality, β-blockers are not without limitations. Accordingly, other ways to regulate G-protein signaling and cardiac proteins involved in cardiac contractility are currently being investigated in the treatment of HF. 45, 46 A better understanding of the molecular processes involved in dysregulation of G-protein signaling in HF is expected to foster the development of improved HF therapies. On the basis of our studies, we identify NDPK-C as a novel potential therapeutic target involved in the regulation of aberrant G-protein signaling and cardiac contractility in HF. Even short-term stimulation of cardiomyocytes with isoprenaline increases the plasma membrane content of NDPK-C and strengthens the interaction between NDPK-C and G proteins, thereby increasing cAMP synthesis. The increased expression or plasma membrane content of NDPK-C in human HF might initially allow the heart to compensate a beginning loss in βAR-induced contractile response in the onset of HF. However, because of the promiscuous nature of NDPK-C, which is able to interact with both Gα s and Gα i , this compensatory mechanism might become detrimental for the heart when the interaction with G i2 increases over time. Along these lines, we show that if Gα i2 levels are enhanced, an increase in NDPK-C abundance reduces cAMP levels ( Figure 8E and 8F) , which may contribute to the detrimental cardiomyocyte phenotype of human HF. Thus, inhibition of NDPK-C might represent a novel adjuvant therapy for patients with end-stage HF.
Limitations
The causes of HF are diverse. We used human ventricular tissue samples from a selected group of patients with end-stage HF. Our finding of increased NDPK-C expression may not hold true for all types and stages of HF. In addition, experimental conditions in vitro may not fully reflect the dynamic regulation of cAMP and contractility in vivo. For example, cAMP levels may change rapidly after tissue excision, and in situ cAMP levels were found to be similar between nonfailing patients and patients with HF, possibly as a result of increased plasma norepinephrine levels counteracting intrinsic downregulation of cAMP in cardiomyocytes. 47 Isoprenaline increased the plasma membrane content of the primarily cytosolic NDPK-C within several hours after stimulation. The mechanisms involved could include translocation, increased protein stability at the plasma membrane, or reduced degradation and should be addressed in future studies.
Here, we characterized the role of NDPK-C in modulating cAMP levels. However, as histidine kinases, NDPKs could also directly phosphorylate various targets within the cardiomyocyte, thereby participating in the control of various cardiac functions. 48 For example, NDPK-B activates transient-receptor potential vallinoid type-5 channels through phosphorylation of histidine 711, thereby controlling Ca 2+ reabsorption in the kidney. 49 Similarly, NDPK-B activates small-conductance Ca 2+ -activated K + channels in vascular smooth muscle cells, controlling neointima formation in carotid arteries. 50 Subsequent work should test these possibilities in the heart.
Conclusions
NDPK-C is indispensable for the interaction between
NDPKs and G proteins and the anchoring of these complexes at the plasma membrane, thereby dynamically regulating cAMP levels and cardiomyocyte contractility. The switch from predominantly Gα s stimulation to Gα i activation by NDPK-C in human HF might cause lower cAMP levels in patients with HF, potentially contributing to the progression of HF. Together, our findings position NDPK-C as a novel critical determinant of βAR/cAMP signaling that could contribute to impaired cardiac function and remodeling in human HF.
